{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Mixed&page=12", "query": { "condition": "Glioma, Mixed", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 286, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Mixed&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Mixed&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T19:10:26.116Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00376818", "title": "Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain and Central Nervous System Tumors", "Psychosocial Effects of Cancer and Its Treatment" ], "interventions": [ { "name": "exercise intervention", "type": "BEHAVIORAL" }, { "name": "educational intervention", "type": "OTHER" }, { "name": "physiologic testing", "type": "OTHER" }, { "name": "management of therapy complications", "type": "OTHER" }, { "name": "mind-body intervention procedure", "type": "BEHAVIORAL" }, { "name": "Measurement of stress-related hormones", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "OTHER", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2006-06", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2012-06-04", "last_synced_at": "2026-10-14T19:10:26.116Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376818" }, { "nct_id": "NCT00100880", "title": "Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "perfusion-weighted magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "diffusion-weighted magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 45, "start_date": "2004-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-14T19:10:26.116Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100880" }, { "nct_id": "NCT00073944", "title": "BCX-1777 in Treating Patients With Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "forodesine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCryst Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-30", "last_synced_at": "2026-10-14T19:10:26.116Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073944" }, { "nct_id": "NCT02924038", "title": "A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Malignant Glioma", "Astrocytoma, Grade II", "Oligodendroglioma", "Glioma, Astrocytic", "Oligoastrocytoma, Mixed" ], "interventions": [ { "name": "IMA950", "type": "BIOLOGICAL" }, { "name": "poly-ICLC", "type": "BIOLOGICAL" }, { "name": "Varlilumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nicholas Butowski", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-04-03", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-10-14T19:10:26.116Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02924038" }, { "nct_id": "NCT00027625", "title": "Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-01-28", "completion_date": "2005-11-01", "has_results": false, "last_update_posted_date": "2018-06-27", "last_synced_at": "2026-10-14T19:10:26.116Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027625" }, { "nct_id": "NCT00498927", "title": "Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunoenzyme technique", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 47, "start_date": "2007-06", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2016-02-29", "last_synced_at": "2026-10-14T19:10:26.116Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00498927" }, { "nct_id": "NCT00003461", "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Metastatic Cancer", "Neuroblastoma" ], "interventions": [ { "name": "surgical procedure", "type": "PROCEDURE" }, { "name": "astatine At 211 monoclonal antibody 81C6", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-02", "completion_date": "2005-02", "has_results": false, "last_update_posted_date": "2014-08-21", "last_synced_at": "2026-10-14T19:10:26.116Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003461" }, { "nct_id": "NCT00217412", "title": "Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Acute Promyelocytic Leukemia (M3)", "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Juvenile Myelomonocytic Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Neuroblastoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Relapsing Chronic Myelogenous Leukemia", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "isotretinoin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 60, "start_date": "2005-08", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2014-06-17", "last_synced_at": "2026-10-14T19:10:26.116Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217412" }, { "nct_id": "NCT00063973", "title": "Cilengitide in Treating Children With Refractory Primary Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Central Nervous System Germ Cell Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma" ], "interventions": [ { "name": "cilengitide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 24, "start_date": "2003-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-14T19:10:26.116Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00063973" }, { "nct_id": "NCT00003466", "title": "Temozolomide in Treating Patients With Progressive Low-Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 100, "start_date": "1998-03", "completion_date": "2005-07", "has_results": false, "last_update_posted_date": "2014-07-09", "last_synced_at": "2026-10-14T19:10:26.116Z", "location_count": 2, "location_summary": "Durham, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003466" } ] }